Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

被引：0

作者：

Ren, S. ^{[1
]}

Wang, X. ^{[2
]}

Han, B. ^{[3
]}

Pan, Y. ^{[4
]}

Zhao, J. ^{[5
]}

Cheng, Y. ^{[6
,10
]}

Hu, S. ^{[7
]}

Liu, T. ^{[8
]}

Li, Y. ^{[9
]}

Cheng, Y. ^{[6
,10
]}

Feng, J. ^{[11
]}

Yi, S. ^{[12
]}

Gu, S. ^{[13
]}

Gao, S. ^{[14
]}

Luo, Y. ^{[15
,16
]}

Liu, Y. ^{[17
]}

Liu, C. ^{[18
]}

Duan, H. ^{[19
]}

Zhou, C. ^{[1
]}

Fan, J. ^{[20
]}

机构：

[1] Shanghai Pulm Hosp, Oncol Dept, Shanghai, Peoples R China

[2] Guangdong Pharmaceut Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China

[3] Shanghai Chest Hosp, Dept Resp, Shanghai, Peoples R China

[4] USTC, Oncol Chemotherapy Dept, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China

[5] Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China

[6] Shandong Univ, Dept Chemotherapy, Qilu Hosp, Jinan, Peoples R China

[7] Hubei Canc Hosp, Dept Thorac Tumor, Wuhan, Peoples R China

[8] Fudan Univ, Dept Med Oncol, Med Oncol Dept, Zhongshan Hosp, Shanghai, Peoples R China

[9] Sichuan Univ, Resp & Crit Care Med, West China Hosp, West China Sch Med, Chengdu, Peoples R China

[10] Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China

[11] Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Affiliated Canc Hosp, Nanjing, Peoples R China

[12] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China

[13] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China

[14] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China

[15] Cent South Univ, Thorac Med Dept, Hunan Canc Hosp, Changsha, Peoples R China

[16] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[17] Zhengzhou Univ, Henan Canc Hosp, Dept Gastroenterol, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[18] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China

[19] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China

[20] Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

43P

引用

页码：S66 / S67

页数：2

共 50 条

[31] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
Descourt, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
[32] A Open-Label Randomised Controlled Trial of First-Line Genexol-PM/CrELBased Paclitaxel plus Cisplatin in Advanced NSCLC Patients
Han, Baohui
Wu, Yi Long
Shi, Meiqi
Gu, Aiqin
Zhang, Xueyan
Jin, Bo
Niu, Yanjie
Dong, Yu
Gu, Ping
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1083 - S1083
[33] KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial
Zhao, Yuanyuan
Chen, Gang
Li, Xingya
Wu, Jingxun
Chang, Baoping
Hu, Sheng
Yang, Shujun
Xu, Ting
Liu, Yilan
Wang, Ni
Zhang, Li
Huang, Yan
CELL REPORTS MEDICINE, 2024, 5 (03)
[34] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.
Meng, Xiangrui
Yang, Xiuli
Hong, Yong-Gui
Zhang, Zhiye
Xia, Jin
Chen, Yunfang
Wu, Tao
Shan, Zheng-Zheng
Fan, Qingxia
Wang, Feng
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Cortellini, Alessio
Tiseo, Marcello
Banna, Giuseppe L.
Cappuzzo, Federico
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Bria, Emilio
Cortinovis, Diego
Grossi, Francesco
Migliorino, Maria R.
Galetta, Domenico
Passiglia, Francesco
Santini, Daniele
Berardi, Rossana
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Tuzi, Alessandro
Gelibter, Alain
Marchetti, Paolo
Macerelli, Marianna
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Gori, Stefania
De Tursi, Michele
Mansueto, Giovanni
Zoratto, Federica
Santoni, Matteo
Tudini, Marianna
Rijavec, Erika
Filetti, Marco
Catino, Annamaria
Pizzutilo, Pamela
Sala, Luca
Citarella, Fabrizio
Marco, Russano
Torniai, Mariangela
Cantini, Luca
Targato, Giada
Sforza, Vincenzo
Nigro, Olga
Ferrara, Miriam G.
D'Argento, Ettore
Buti, Sebastiano
Bordi, Paola
Antonuzzo, Lorenzo
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221
[36] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Alessio Cortellini
Marcello Tiseo
Giuseppe L. Banna
Federico Cappuzzo
Joachim G. J. V. Aerts
Fausto Barbieri
Raffaele Giusti
Emilio Bria
Diego Cortinovis
Francesco Grossi
Maria R. Migliorino
Domenico Galetta
Francesco Passiglia
Daniele Santini
Rossana Berardi
Alessandro Morabito
Carlo Genova
Francesca Mazzoni
Vincenzo Di Noia
Diego Signorelli
Alessandro Tuzi
Alain Gelibter
Paolo Marchetti
Marianna Macerelli
Francesca Rastelli
Rita Chiari
Danilo Rocco
Stefania Gori
Michele De Tursi
Giovanni Mansueto
Federica Zoratto
Matteo Santoni
Marianna Tudini
Erika Rijavec
Marco Filetti
Annamaria Catino
Pamela Pizzutilo
Luca Sala
Fabrizio Citarella
Russano Marco
Mariangela Torniai
Luca Cantini
Giada Targato
Vincenzo Sforza
Olga Nigro
Miriam G. Ferrara
Ettore D’Argento
Sebastiano Buti
Paola Bordi
Lorenzo Antonuzzo
Cancer Immunology, Immunotherapy, 2020, 69 : 2209 - 2221
[37] Updated data from FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase 2 trial
Chen, Li
Jiang, Yi-Zhou
Wu, Songyang
Wu, Jiong
Di, Genhong
Liu, Guangyu
Yu, Keda
Fan, Lei
Li, Junjie
Hou, Yifeng
Hu, Zhen
Chen, Canming
Huang, Xiaoyan
Cao, Ayong
Hu, Xin
Zhao, Shen
Ma, Xiaoyan
Zhu, Xiaoyu
Zou, Jianjun
Yang, Wentao
Wang, Zhonghua
Shao, Zhi-ming
CANCER RESEARCH, 2022, 82 (04)
[38] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Makharadze, T.
Paydas, S.
Nechaeva, M.
Seebach, F.
Weinreich, D. M.
Yancopoulos, G. D.
Gullo, G.
Lowy, I.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
[39] Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial
Jiang, Lijuan
Zheng, Xia
Wei, Wensu
Peng, Yulu
Wang, Deling
Zhang, Zhiling
Guo, Shengjie
Han, Hui
Cai, Xiuyu
Zhou, Fangjian
Dong, Pei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[40] Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Ren, Shengxiang
Chen, Jianhua
Xu, Xingxiang
Jiang, Tao
Cheng, Ying
Chen, Gongyan
Pan, Yueyin
Fang, Yong
Wang, Qiming
Huang, Yunchao
Yao, Wenxiu
Wang, Rui
Li, Xingya
Zhang, Wei
Zhang, Yanjun
Hu, Sheng
Guo, Renhua
Shi, Jianhua
Wang, Zhiwu
Cao, Peiguo
Wang, Donglin
Fang, Jian
Luo, Hui
Geng, Yi
Xing, Chunyan
Lv, Dongqing
Zhang, Yiping
Yu, Junyan
Cang, Shundong
Yang, Zeyu
Shi, Wei
Zou, Jianjun
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 544 - 557

← 1 2 3 4 5 →